Corbevax is the first indigenously developed 'Receptor Binding Domain Protein Sub-unit Vaccine' against Covid-19. The 'protein sub-unit vaccine' strengthens the immune response rather than fighting the virus as a whole.
It Contains a harmless spike (S) protein. When the immune system recognizes the protein, it produces antibodies to fight the actual infection.
It is given by the intramuscular route, with two doses given at 28-day intervals. It is stored at 2 to 8 °C.
It has been developed by Biological E Limited's (BE) based in Hyderabad.
Recently, this vaccine has been approved by the Drug Controller General of India (DCGI) for emergency use in people aged between 12 to 18 years, while its use in adults has already been approved.